-
Mashup Score: 2
New data indicates that an oral TYK2 inhibitor known as NDI-034858 showed strong results for psoriasis patients in a recent phase 2b trial.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Risankizumab Led to Improvements for Psoriasis Patients Unresponsive to Secukinumab, Ixekizumab - 1 year(s) ago
New data has indicated that patients with psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
New data presented at #AAD2023 indicates that patients with #psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor. Check out the data here: https://t.co/97XuZ2k0SK #AAD23 #dermatology #plaquepsoriasis
-
-
Mashup Score: 0HCPLive - Clinical news for connected physicians - 1 year(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician…
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Setting up for an interview at #AAD2023 with Dr. Jeffrey Cohen from @YaleMedicine, in a discussion about the latest updates on psoriasis therapies. Follow @MDMagazine for more updates on new data and interviews with key opinion leaders: https://t.co/qzWLcKaHkR #AAD23 #psoriasis https://t.co/gwkluHXLMj
-
-
Mashup Score: 0
Late-breaking data on roflumilast cream for eczema patients in two phase 3 trials titled INTEGUMENT-1 and INTEGUMENT-2 showed strong results for the drug.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Roflumilast 0.15% once-daily was found to be effective at improving #AtopicDermatitis across multiple efficacy endpoints and produced favorable safety & tolerability. Check out the data here: https://t.co/zWWfs5xFeZ #AAD23 #roflumilast #AAD2023
-
-
Mashup Score: 0Lawrence Eichenfield, MD: Roflumilast Cream for Adults, Children with Atopic Dermatitis - 1 year(s) ago
In a new interview, Eichenfield discussed the background of his presentation on late-breaking data from the INTEGUMENT-1 and INTEGUMENT-2 trials on roflumilast for atopic dermatitis.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Lawrence F. Eichenfield, MD of @UCSDMedSchool & @radychildrens spoke at #AAD2023 about the INTEGUMENT-1 and INTEGUMENT-2 studies on roflumilast for atopic dermatitis. Check out this interview segment here: https://t.co/F6r4cmYtG3 #eczema #roflumilast #AAD23
-
-
Mashup Score: 0Dermatology | Medical News & Expert Insight | HCPLive - 1 year(s) ago
The dermatology condition center is a comprehensive resource for clinical news and expert insights on dermatology. Read more at HCPLive.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Another exciting day of #AAD2023 conference coverage! For today's latest updates on late-breaking data and interviews with key opinion leaders, follow @MDMagazine: https://t.co/9HWkuhnhjc #dermatology #AAD23 https://t.co/pEmoDLujWD
-
-
Mashup Score: 0Nemolizumab Treatment Led to Improved Skin Lesions, Itch for Prurigo Nodulari Patients - 1 year(s) ago
Late-breaking phase 3 data on nemolizumab monotherapy indicates substantial improvement in key primary and secondary endpoints for prurigo nodularis patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Late-breaking phase 3 data presented at #AAD23 on nemolizumab monotherapy indicates substantial improvement in key primary & secondary endpoints for #PrurigoNodularis patients. Check out the data here: https://t.co/EWttwAmlyE #dermatology #PN #AAD2023
-
-
Mashup Score: 0HCPLive - Clinical news for connected physicians - 1 year(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician…
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Want to learn more about the latest news on data presented at #AAD2023? Follow @MDMagazine or check out our coverage here: https://t.co/a8rPUYVi1r #AAD23 #AAD2023 #dermatology https://t.co/E66fcCuuJp
-
-
Mashup Score: 0Delgocitinib Significantly Improves Chronic Hand Eczema, Quality of Life at 16 Weeks - 1 year(s) ago
New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
New phase 3 data: delgocitinib achieves significant chronic hand eczema improvement at 16 weeks. #AAD2023 #AAD23 https://t.co/8W96D5q1CH
-
-
Mashup Score: 1John Harris, MD, PhD: Year 1 of Ruxolitinib Cream for Vitiligo - 1 year(s) ago
The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
If you enjoyed @HarrisVitiligo's Twitter takeover during the #AAD23 vitiligo symposium this morning, be sure to check out part 1 of his pre-meeting interview on the biggest developments in #vitiligo today: https://t.co/rusH82xrgD
-
New data presented at #AAD2023 showed that an oral TYK2 inhibitor (NDI-034858) led to positive results for psoriasis patients in a recent phase 2b trial. Learn more about the late-breaking data here: https://t.co/ujr9HFry4m #psoriasis #AAD23